A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology-Reference-Cited by-同舟云学术

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

Published:2013-06-28 Issue:7 Volume:24 Page:1256-1263
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Jeffrey Scott C.,Burke Patrick J.¹,Lyon Robert P.¹,Meyer David W.¹,Sussman Django¹,Anderson Martha¹,Hunter Joshua H.¹,Leiske Chris I.¹,Miyamoto Jamie B.¹,Nicholas Nicole D.¹,Okeley Nicole M.¹,Sanderson Russell J.¹,Stone Ivan J.¹,Zeng Weiping¹,Gregson Stephen J.²,Masterson Luke²,Tiberghien Arnaud C.²,Howard Philip W.²,Thurston David E.³,Law Che-Leung¹,Senter Peter D.¹

Affiliation:

1. Department of Research & Translational Medicine, Seattle Genetics, Inc., Bothell, Washington 98021, United States

2. Spirogen Ltd., QMB Innovation Centre, 42 New Road, London E1 2AX, United Kingdom

3. Department of Pharmacy, Institute of Pharmaceutical Sciences, King’s College London, Britannia House, 7 Trinity Street, London SE1 1DB

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/bc400217g

Reference40 articles.

1. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

2. Potent antibody drug conjugates for cancer therapy

3. Antibody-Drug Conjugates in Cancer Therapy

4. Design, Synthesis, and Biological Evaluation of Antibody−Drug Conjugates Comprised of Potent Camptothecin Analogues

5. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system

Cited by 223 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed dose selection for an investigational human epidermal growth factor receptor 2 antibody–drug conjugate FS‐1502 in patients with human epidermal growth factor receptor 2‐expressing advanced malignant solid tumours;British Journal of Clinical Pharmacology;2024-01-25

2. Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability;Cell Reports;2023-12

3. Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody–Drug Conjugates;Bioconjugate Chemistry;2023-11-20

4. Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model;Nature Communications;2023-10-12

5. The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress;Bioconjugate Chemistry;2023-10-11